AvantorAVTR
About: Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Employees: 13,500
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1.03% more ownership
Funds ownership: 99.39% [Q3] → 100.42% (+1.03%) [Q4]
5% less funds holding
Funds holding: 503 [Q3] → 478 (-25) [Q4]
17% less capital invested
Capital invested by funds: $17.5B [Q3] → $14.4B (-$3.05B) [Q4]
19% less repeat investments, than reductions
Existing positions increased: 166 | Existing positions reduced: 205
22% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 79
23% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 10 (-3) [Q4]
64% less call options, than puts
Call options by funds: $52.6M | Put options by funds: $145M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target | 8%upside $14 | Neutral Downgraded | 29 Apr 2025 |
RBC Capital Conor McNamara 17% 1-year accuracy 7 / 41 met price target | 54%upside $20 | Outperform Maintained | 28 Apr 2025 |
Stifel Daniel Arias 15% 1-year accuracy 3 / 20 met price target | 8%upside $14 | Hold Downgraded | 28 Apr 2025 |
Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target | 15%upside $15 | Overweight Maintained | 28 Apr 2025 |
Morgan Stanley Tejas Savant 26% 1-year accuracy 5 / 19 met price target | 15%upside $15 | Equal-Weight Downgraded | 28 Apr 2025 |
Financial journalist opinion
Based on 11 articles about AVTR published over the past 30 days
